The U.S. government asked a federal judge to overturn a recent case which found Gilead did not infringe on the CDC’s patents for a pair of groundbreaking HIV pills. […]
“It’s a setback in patient safety and surveillance,” one expert said, “and will leave us with an insufficient regulatory system for identifying unsafe devices.” […]
As new cancer drugs arrive, regulators and doctors still struggle with when to use drugs based on earlier data and when to wait for survival data. #ASCO23 […]
Proving a meaningful survival benefit for patients with a type of blood cancer represents another milestone for CAR-T therapy. #ASCO23 […]
Carbon Health’s speedy rollout of AI note-taking hints at how impatient health care companies are to save time and money on medical records. […]
A U.S. appeals court ruled that Purdue Pharma can shield its owners from lawsuits over the company’s role in the opioid crisis as part of a bankruptcy settlement. […]
The European Medicines Agency recommended revoking marketing authorization for a Novartis sickle cell disease drug called Adakveo. […]
“We’ve lost an opportunity to have direct government purchases of hundreds of thousands of doses of generic Truvada at a lower cost to dramatically lower HIV infections,” said Peter Staley… […]
The U.S. Supreme Court upheld a ruling that Amgen failed to disclose sufficient information about patent claims for its cholesterol drug Repatha. […]
In a rare partnership, heavyweight tech venture firms General Catalyst and Andreessen Horowitz are co-leading a $50 million seed round aimed at exploring large language models in health care. […]
Copyright © 2023 Biotech Networks, LLC
